Apple App Store Injunction Largely Upheld as Appeals Court Rules on Epic Games Case 
United Airlines Tokyo-Bound Flight Returns to Dulles After Engine Failure 
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
Intel’s Testing of China-Linked Chipmaking Tools Raises U.S. National Security Concerns 
Moore Threads Stock Slides After Risk Warning Despite 600% Surge Since IPO 
Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions 
EU Court Cuts Intel Antitrust Fine to €237 Million Amid Long-Running AMD Dispute 
Trello Outage Disrupts Users as Access Issues Hit Atlassian’s Work Management Platform 
China Adds Domestic AI Chips to Government Procurement List as U.S. Considers Easing Nvidia Export Curbs 
Evercore Reaffirms Alphabet’s Search Dominance as AI Competition Intensifies 
SpaceX Edges Toward Landmark IPO as Elon Musk Confirms Plans 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
Rio Tinto Signs Interim Agreement With Yinhawangka Aboriginal Group Over Pilbara Mining Operations 
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
Westpac Director Peter Nash Avoids Major Investor Backlash Amid ASX Scrutiny 
Air Force One Delivery Delayed to 2028 as Boeing Faces Rising Costs 
Jiangsu Hengrui Pharmaceuticals Co (HK:1276) made a powerful entrance on the Hong Kong Stock Exchange on Friday, with shares soaring over 37% in early trading after a $1.27 billion IPO. The offering was priced at HK$44.05—at the top of its range—reflecting strong investor appetite for the Chinese biopharmaceutical giant.
Shares opened at HK$57.10, marking a 29.6% jump from the offer price, and peaked at HK$60.20 shortly after the market opened. The robust debut highlights renewed investor confidence in Hong Kong’s IPO market, which has seen a notable resurgence, particularly from mainland Chinese companies pursuing dual listings.
Hengrui, already publicly traded in Shanghai, is one of China’s top drugmakers, specializing in oncology, innovative therapies, and biosimilars. The company plans to allocate IPO proceeds to accelerate clinical trials, scale production capabilities, and support global expansion. The strategic move is aimed at strengthening its international footprint and enhancing its competitiveness in the global pharmaceutical industry.
The timing of Hengrui’s successful listing coincides with the broader uptick in Hong Kong’s capital markets. Earlier this week, Contemporary Amperex Technology Co Ltd (CATL) (HK:3750) also debuted strongly, underscoring heightened interest in high-growth Chinese firms across sectors.
Jiangsu Hengrui’s performance signals positive momentum for biotech and pharmaceutical IPOs in Asia, particularly as global investors look toward companies with robust pipelines and innovation-driven strategies. With a clear focus on global growth and R&D, Hengrui's dual listing positions it to attract more institutional interest while reinforcing Hong Kong’s status as a hub for health tech and biotech capital.
